Expression of angiogenic factors in endometriosis: Relationship to fibrinolytic and metalloproteinase systems

Human Reproduction

Volumn 22, Issue 8, 2007, Pages 2120-2127

  Gilabert Estelles J ^a   Ramon L A ^b   Espana F ^b   Gilabert, J ^a   Vila, V ^b   Reganon E ^b   Castello R ^b   Chirivella, M ^b   Estellés, Amp ^b  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Angiogenesis; Endometriosis; Fibrinolytic system; Metalloproteinase system; VEGF

Indexed keywords

ANGIOGENIC FACTOR; FIBRINOLYTIC FACTOR; MESSENGER RNA; METALLOPROTEINASE; STROMELYSIN; THROMBOSPONDIN 1; UROKINASE; VASCULOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; ENDOMETRIOSIS; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PERITONEAL FLUID LEVEL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 34547785068     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dem149     Document Type: Article

References (53)

1. American Society for Reproductive Medicine, Revised American Society for Reproductive Medicine Classification of endometriosis: 1996. Fertil Steril 1997; 67:817-821.
2. Armstrong LC, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol 2003;22:63-71.
3. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor id its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1 1356-1370.
4. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, Taylor GA, Folkman J, D'Amato RJ. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84(Suppl 2):1144-1155.
5. Breier G, Damert A, Plate KH, Risau W. Angiogenesis in embryos and ischemic diseases. Thromb Haemost 1997;78:678-683.
6. Bruse C, Bergqvist A, Carlstrom K, Fianu-Jonasson A, Lecander I, Astedt B. Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women. Fertil Steril 1998;70 821-826.
7. Bruse C, Radu D, Bergqvist A. In situ localization of mRNA for the fibrinolytic factors uPA, PAL 1 and uPAR in endometriotic and endometrial tissue. Mol Hum Reprod 2004;10:159-166.
8. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
9. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9 653-660.
10. Castelló R, Estellés A, Vázquez C, Falcó C, España F, Almenar SM, Fuster C, Aznar J. Quantitative 'real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1 (PAI-1) and tissue metalloproteinase inhibitor type 1 (TIMP-1) gene expression in primary breast cancer. Clin Chem 2002; 48:1288-1295.
11. Chung HW, Wen Y, Chun SH, Nezhat C, Woo BH, Polan ML. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in ectopic and eutopic endometrium. in women with endometriosis: A rationale for endometriotic invasiveness. Fertil Steril 2001;75:152-159.
12. Cox KE, Piva M, Sharpe-Timms KL. Differential regulation of matrix metalloproteinase-3 gene expression in endomendotic lesions compared with endometrium. Biol Reprod 2001;65:1297-1303.
13. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M. Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod 1998 13:1686-1690.
14. Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, España F, Loskutoff DJ, Schleef RR. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84:143-150.
15. Fasciani A, D'Ambrogio G, Bocci G, Monti M, Genazzani AR, Artini PG. High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Mol Hum Reprod 2000;6 50-54.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
17. Gilabert-Estellés J, Castelló R, Gilabert J, Ramón LA, España F, Romeu A, Estellés A. Plasminogen activators and plasminogen activator inhibitors in endometriosis. In: "Tissue Remodeling Factors in the Physiology and Pathophysiology of the Female Reproductive Tract". Front Biosci 2005;10:1162-1176.
18. Gilabert-Estellés J, Estellés A, Gilabert J, Castelló R, España F, Falcó C, Romeu A, Chirivella M, Zorio E, Aznar J et al. Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis. Hum Reprod 2003;18: 1516-1522.
19. Girling JE, Rogers PA. Recent advances in endometrial angiogenesis research. Angiogenesis 2005;8:89-99.
20. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-1799.
21. Healy DL, Rogers PA, Hii L, Wingfield M. Angiogenesis: A new theory for endometdosis. Hum Reprod Update 1998;4:736-740.
22. Hull ML, Charnock-Jones DS, Chan CL, Bruner-Tran KL, Osteen KG, Tom BD, Fan TP, Smith SK. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003;88:2889-2899.
23. Iruela-Arispe ML, Porter P, Bornstein P, Sage EH. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest 1996;97:403-412.
24. Iyer S, Leonidas DD, Swaminathan GJ, Maglione D, Battisti M, Tucci M, Persico MG, Acharya KR. The crystal structure of human placenta growth factor-1 (PIGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem 2001;276:12153-12161.
25. Kawano Y, Nakamura S, Nasu K, Fukuda J, Narahara H, Miyakawa I. Expression and regulation of thrombospondin-1 by human endometrial stromal cells. Fertil Steril 2005;83:1056-1059.
26. Koninckx PR, Kennedy SH, Barlow DH. Endornetriotic disease: The role of peritoneal fluid. Hum Reprod Update 1998;4:741-751.
27. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21: 262-268.
28. Lembessis P, Milingos S, Michalas S, Milingos D, Creatsas G, Sourla A, Koutsilieris M. Urokinase-type plasminogen activator and insulin-like growth factor binding protein 3 mRNA expression in endometnotic lesions and eutopic endometrium: Implications for the pathophysiology of endometriosis. Ann N Y Acad Sci 2003;997:223-228.
29. Li XF, Charnock-Jones DS, Zhang E, Hiby S, Malik S, Day K, Licence O, Bowen JM, Gardner L, King A et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab 2001;86:1823-1834.
30. Lijnen HR. Matriz metalloproteinases and cellular fibrinolytic activity. Biochemistry 2002;G7:92-98.
31. Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis. Fertil Steril 2000;73:166-170.
32. Martinez-Roman S, Balasch J, Creus M, Fabregues F, Carmona F, Vilella R, Vanrell JA. Immunological factors in endometriosis-associated reproductive failure: Studies in fertile and infertile women with and without endometriosis. Hum Reprod 1997;12:1794-1799.
33. McLaren J, Prentice A, Charnock-Jones DS, Smith SK. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996;11:220-223.
34. McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update 2000;6:45-55.
35. Na YJ, Yang SH, Baek DW, Lee DH, Kim KH, Choi YM, Oh ST, Hong YS, Kwak JY, Lee KS et al. Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes. Hum Reprod 2006;21:1846-1855.
36. Nap AW, Griffioen AW, Dunselman GA, Bouma-TerSteege JC, Thijssen VL, Evers JL, Groothuis PG. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89:1089-1095.
37. Nisolle M, Casanas-Roux F, Anaf V, Mine JM, Donnez J. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681-684.
38. Osteen KG, Bruner KL, Sharpe-Timms KL. Steroid and growth factor regulation of matrix metalloproteinase expression and endometriosis. Semin Reprod Endocrinol 1996;14:247-255.
39. Pellicer A, Navarro J, Bosch E, Garrido N, Garcia-Velasco JA, Remohí J, Simón C. Endometrial quality in infertile women with endometriosis. Ann N Y Acad Sci 2001;943:122-130.
40. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Tromb Vasc Biol 2001;21:1104-1117.
41. Print C, Valtola R, Evans A, Lessan K, Malik S, Smith S. Soluble factors from human endometrium promote angiogenesis and regulate the endothelial cell transcriptome. Hum Reprod 2004;19:2356-2366.
42. Ramón L, Gilabert-Estellés J, Castellós R, Gilabert J, España F, Romeu A, Chirivella M, Azaar J, Estellés A. mRNA quantitative analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using real-time reverse transcription-PCR assay. Hum Reprod 2005;20:272-278.
43. Sharpe-Timms KL. Endometrial anomalies in women with endometriosis. Ann N Y Acad Sci 2001;943:131-147.
44. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB, Taylor RN. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;81:31,12-3118.
45. Sillem M, Prifti S, Koch A, Neher M, Jauckus J Runnebaum B. Regulation of matrix metalloproteinases and their inhibitors in uterine endomotrial cells of patients with and without endometriosis. Eur J Obstet Gynecol Reprod Biol 2001;95:167-174.
46. Suzumori N, Sugiura-Ogasawara M, Katano K, Suzumiori K. Women with endometriosis have increased levels of placental growth factor in the peritoneal fluid compared with women with cystadenomas. Hum Reprod 2003;18:2595-2598.
47. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002;955:89-100.
48. Takehara M, Ueda M, Yamashita Y, Terai Y, Hung YC, Ueki M. Vascular endothelial growth factor A and C gene expression in endometriosis. Hum Pathol 2004;35:1369-1375.
49. Tan XJ, Lang JH, Liu DY, Shen K, Leng JH, Zhu L. Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. Fertil Steril 2002;78:148-153.
50. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003;88:5555 -5563.
51. Ugwu F, Lemmens G, Collen D, Lijnen HR. Modulation of cell-associated plasminogen activation by stromelysin-I (MMP-3). Thromb Haemost 1999;82:1127-1131.
52. Wu Y, Kajdacsy-Balla A, Strawn E, Basir Z, Halverson G, Jailwala, P, Wang Y, Wang X, Ghosh S, Guo SW et al. Transcriptional characterizations of differences between eutopic and ectopic endometnum. Endocrinology 2006;147:232-246.
53. Zhou YH, Tan F, Hess KR, Yung WK. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res 2003;9:3369-3375.